PBMC Gene Expression Biomarkers for Peg-IFN-α Response in Chronic Hepatitis B

A clinical study dataset investigating the correlation between altered expression of ADAR1, N4BP1, and PSME1 mRNAs in peripheral blood mononuclear cells (PBMCs) and therapeutic outcomes in HBeAg-negative chronic hepatitis B patients treated with Peg-IFN-α. The prospective study followed patients for 48 weeks, categorizing them into virological and serological response groups. The dataset, authored by Hao Pang and last updated in April 2026, is shared under a CC-BY-4.0 license.

Use Cases

• Predicting virological response to Peg-IFN-α treatment based on ADAR1, N4BP1, and PSME1 mRNA levels.
• Identifying biomarkers for early HBsAg clearance based on dynamic gene expression changes.
• Evaluating the diagnostic performance of candidate biomarkers using ROC curve analysis.
• Conducting multivariate analysis to find independent predictors of therapeutic outcomes.

Strengths

• Includes specific Area Under the Curve (AUC) values for biomarker performance (e.g., 0.9230 for ADAR1 predicting VR at week 24).
• Reports clear clinical response rates (47.25% VR and 35.16% SR).
• Data is from a prospective study with a 48-week follow-up period.
• Results are supported by multivariate analysis identifying independent associations.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (16.8 KB), indicating limited scope.

Provenance

Source

figshare, author Hao Pang.

Collection Method

Prospective clinical study using real-time quantitative PCR to detect mRNA expression levels in PBMCs.

Time Range

Study follow-up period of 48 weeks.

Freshness

Last updated 2026-04-13 04:36:09; freshness should be verified.

Geography

null